JP2018504141A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504141A5
JP2018504141A5 JP2017556782A JP2017556782A JP2018504141A5 JP 2018504141 A5 JP2018504141 A5 JP 2018504141A5 JP 2017556782 A JP2017556782 A JP 2017556782A JP 2017556782 A JP2017556782 A JP 2017556782A JP 2018504141 A5 JP2018504141 A5 JP 2018504141A5
Authority
JP
Japan
Prior art keywords
government
awarded
health
certain rights
national institutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013765 external-priority patent/WO2016118433A1/en
Publication of JP2018504141A publication Critical patent/JP2018504141A/ja
Publication of JP2018504141A5 publication Critical patent/JP2018504141A5/ja
Pending legal-status Critical Current

Links

JP2017556782A 2015-01-20 2016-01-17 非標的化アデノウイルス変異体および関連する方法 Pending JP2018504141A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105284P 2015-01-20 2015-01-20
US62/105,284 2015-01-20
PCT/US2016/013765 WO2016118433A1 (en) 2015-01-20 2016-01-17 Detargeted adenovirus variants and related methods

Publications (2)

Publication Number Publication Date
JP2018504141A JP2018504141A (ja) 2018-02-15
JP2018504141A5 true JP2018504141A5 (enExample) 2019-02-07

Family

ID=56417617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556782A Pending JP2018504141A (ja) 2015-01-20 2016-01-17 非標的化アデノウイルス変異体および関連する方法

Country Status (4)

Country Link
US (3) US10376549B2 (enExample)
EP (1) EP3247807B1 (enExample)
JP (1) JP2018504141A (enExample)
WO (1) WO2016118433A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
ES2941339T3 (es) 2016-03-31 2023-05-22 The European Molecular Biology Laboratory Vehículos de suministro derivados de la proteína de la cubierta adenovírica
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
EP3812465A1 (en) 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (enExample) 1968-10-17 1970-08-24
JPH06508603A (ja) * 1991-02-14 1994-09-29 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション ＨＩＶ　Ｔａｔタンパク質に対する新規インテグリン特異性
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
WO2001091802A1 (en) * 2000-05-30 2001-12-06 Baylor College Of Medicine Chimeric viral vectors for gene therapy
WO2002081497A2 (en) * 2001-04-04 2002-10-17 University Of Rochester αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE
WO2003029448A1 (en) 2001-09-29 2003-04-10 Yun, Chae-Ok Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus
US20040002060A1 (en) * 2002-01-24 2004-01-01 Novartis Ag Fiber shaft modifications for efficient targeting
JP4328116B2 (ja) * 2003-03-25 2009-09-09 国立医薬品食品衛生研究所長 変異型アデノウイルスベクター
WO2005027711A2 (en) * 2003-05-01 2005-03-31 University Of Washington Capsid-modified adenovirus vectors and methods of using the same
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
CN102014948A (zh) * 2008-02-07 2011-04-13 安德鲁·贝克 腺病毒向性的调节
BR112012010824A2 (pt) * 2009-11-09 2018-03-06 Genvec Inc adenovirus simios e métodos de uso

Similar Documents

Publication Publication Date Title
JP2018504141A5 (enExample)
JP2021502979A5 (enExample)
JP2021503478A5 (enExample)
WO2018081648A3 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
JP2021500894A5 (enExample)
EP3762031A4 (en) ANTI-CLAUDINE ANTIBODIES 18.2 AND THEIR USES
JP2018012698A5 (enExample)
JP2020010717A5 (enExample)
JP2018100276A5 (enExample)
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
JP2016196495A5 (enExample)
JP2018533683A5 (enExample)
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
JP2016028081A5 (enExample)
JP2019536002A5 (enExample)
HUE062189T2 (hu) Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
TWD173737S (zh) 肌肉鍛鍊機器
JP2018064407A5 (enExample)
JP2017537928A5 (enExample)
EP3415518A4 (en) MACROCYCLUS AND COMPOSITION THEREOF
JP2015186128A5 (enExample)